Menopausal hormone therapy, depression, headache, vasomotor symptoms and absence from work: results from 3 years follow up in a Dutch gynecology clinic

Maturitas ◽  
2015 ◽  
Vol 81 (1) ◽  
pp. 127-128
Author(s):  
Mojdeh Shayesteh ◽  
Ingrid Pinas
Keyword(s):  
Hormone Therapy ◽  
Menopausal Hormone Therapy ◽  
Vasomotor Symptoms ◽  
Absence From Work

The role of orexin A in pathophysiological mechanisms of sleep disorder in postmenopausal women

GYNECOLOGY ◽  
2020 ◽  
Vol 22 (1) ◽  
pp. 50-54
Author(s):  
Zukhra Kh. Ebzieva ◽  
Svetlana V. Yureneva ◽  
Tatiana Yu. Ivanets
Keyword(s):  
Hormone Therapy ◽  
Sleep Disorder ◽  
Postmenopausal Women ◽  
Menopausal Hormone Therapy ◽  
Reproductive Age ◽  
Vasomotor Symptoms ◽  
Women Of Reproductive Age ◽  
Orexin A ◽  
Group 1

Aim. To conduct a comparative analysis of serum orexin A levels in women of different age periods with and without sleep disorder and vasomotor symptoms. To evaluate the dynamics of orexin A levels under menopausal hormone therapy. Materials and methods. The study included 50 postmenopausal women and 30 women of reproductive age with a regular menstrual cycle. Using block randomization, patients are divided into 3 groups: group 1 (main group), n=25, -STRAW+ 10 (+1b and +1c), patients with sleep disorder and vasomotor symptoms; group 2 (comparison group), n=25, STRAW+ 10 (+1b and +1c), patients with vasomotor symptoms without sleep disorder; group 3 (control group), n=30, STRAW+ 10 (-4), women of reproductive age without sleep disorder. Group 1 patients were given menopausal hormone therapy. A comparative analysis was carried out using the questionnaire for assessing menopausal symptoms severity by the Greene Scale (the Greene Climacteric Scale) and Rating Scale for subjective sleep characteristics. After 12 weeks of treatment, a control examination was performed. Results. In group 1 women, the serum orexin A levels were significantly higher compared to the women without the symptoms. The link between the orexin A levels and menopause syndrome severity was established. A significant decrease in the menopausal symptoms severity after 12 weeks of menopausal hormone therapy was shown. It was accompanied by a 1,3-fold decrease in orexin A levels. Conclusions. The obtained data indicate the possible role of orexin A and the orexin neuropeptide system in the pathogenesis of sleep disorder and vasomotor symptoms in postmenopausal women.

Abstract T MP67: Physical Activity Reduces Stroke Risk Among Women in the California Teachers Study Cohort

Stroke ◽  
2014 ◽  
Vol 45 (suppl_1) ◽  
Author(s):  
Sophia S Wang ◽  
Kamakshi Lakshminarayan ◽  
Mitchell Elkind ◽  
Jenna Voutsinas ◽  
James Lacey ◽  
...  
Keyword(s):  
Physical Activity ◽  
Hormone Therapy ◽  
Stroke Risk ◽  
Menopausal Hormone Therapy ◽  
Study Cohort ◽  
Prevention Strategies ◽  
Stroke Risk Factors ◽  
Increased Risk ◽  
Post Menopausal

Background: Major modifiable stroke risk factors are well-established, yet strategies for effective prevention remain challenging. Developing stroke prevention strategies for women is critical due to: (i) the higher fatality and disability rate that women suffer compared to men, (ii) the unique risks to women such as from post-menopausal hormone therapy use, and (iiii) the aging female population. We evaluated three important modifiable stroke risk factors- obesity, hormone therapy, and physical activity, in the California Teachers Study cohort to identify potential stroke prevention strategies. Methods: The California Teachers Study comprises 133,479 women who enrolled in 1995 and have since been continuously followed. Using linked California state hospitalization data from 1996-2010, 3126 stroke events were defined as ischemic (N=2416; ICD-9 433, 434, 436) or hemorrhagic (N=710; ICD-9 430-432, excluding 432.1) and were validated by medical record review. Information about obesity, physical activity, hormone therapy, and medical history was collected at baseline and in follow-up questionnaires. Multivariable-adjusted hazards ratios and 95% confidence intervals were estimated by fitting Cox proportional hazards models with follow-up through 2010. Results: Consistent with previous reports, current post-menopausal hormone therapy use was associated with a 1.3-fold increased risk for stroke (95% CI=1.03-4.85). Moderate to strenuous physical activity in the 3 years before enrollment (but not lifetime activity) decreased stroke risk by 20% (HR=0.79, 95% CI=0.71-0.98). This decreased risk among physically active women was similar among current hormone therapy users, and appears to counteract the increased risk observed with current hormone therapy use. We found no association between obesity and stroke that was independent of diabetes. Conclusions: Recent physical activity reduces stroke risk and appears to counteract the increased risk associated with post-menopausal hormone therapy use.

scholarly journals Risks, Benefits, and Treatment Modalities of Menopausal Hormone Therapy: Current Concepts

2021 ◽  
Vol 12 ◽  
Author(s):  
Jaya Mehta ◽  
Juliana M. Kling ◽  
JoAnn E. Manson
Keyword(s):  
Hormone Therapy ◽  
Clinical Decision Making ◽  
Clinical Decision ◽  
Menopausal Hormone Therapy ◽  
Treatment Modalities ◽  
Prescribing Practices ◽  
Post Intervention ◽  
Comprehensive Overview ◽  
Risks And Benefits

Menopausal hormone therapy (HT) prescribing practices have evolved over the last few decades guided by the changing understanding of the treatment’s risks and benefits. Since the Women’s Health Initiative (WHI) trial results in 2002, including post-intervention analysis and cumulative 18-year follow up, it has become clear that the risks of HT are low for healthy women less than age 60 or within ten years from menopause. For those who are experiencing bothersome vasomotor symptoms, the benefits are likely to outweigh the risks in view of HT’s efficacy for symptom management. HT also has a role in preventing osteoporosis in appropriate candidates for treatment. A comprehensive overview of the types, routes, and formulations of currently available HT, as well as HT’s benefits and risks by outcomes of interest are provided to facilitate clinical decision making.

scholarly journals Alternatives of menopausal hormone therapy

2016 ◽  
Vol 69 (5-6) ◽  
pp. 177-182
Author(s):  
Ranko Kutlesic ◽  
Jasmina Popovic ◽  
Milan Stefanovic ◽  
Predrag Vukomanovic ◽  
Bojan Lukic ◽  
...  
Keyword(s):  
Hormone Therapy ◽  
Selective Serotonin Reuptake Inhibitors ◽  
Water Solution ◽  
Hot Flashes ◽  
Menopausal Symptoms ◽  
Menopausal Hormone Therapy ◽  
Vasomotor Symptoms ◽  
Long Term Effects ◽  
Alternative Treatments ◽  
Adequate Diet

Introduction. It has been generally accepted that the benefits of menopausal hormone therapy outweigh the risks, but there are still some concerns about the administration of menopausal hormone therapy, which has introduced alternative treatments. Pharmacological Alternatives. Central alpha-2 agonist clonidine is only marginally more effective than placebo, and significantly less effective than estrogen. Antiepileptic drug gabapentin reduces hot flashes; however, it is less effective than estrogen. Selective serotonin reuptake inhibitors (paroxetine and fluoxetine) and selective noradrenaline reuptake inhibitors (venlafaxine) reduce vasomotor symptoms and improve depression, anxiety and sleep. Results of studies about dehydroepiandrosterone effects on menopausal symptoms are inconsistent and additional investigations are needed. Non-Pharmacological Alternatives. Stellatum ganglion blockade is a successful treatment for reducing vasomotor symptoms in patients with contraindications for menopausal hormone therapy. Efficacy of acupuncture, homeopathy and reflexology should be proved by adequate studies. Phytoestrogens could reduce vasomotor symptoms but to a lesser extent than conventional menopausal hormone therapy. However, they have not been proved yet to provide cardiovascular protection and prevention of osteoporosis, nor they could be recommended instead of traditional menopausal hormone therapy. There is a concern about their undesirable effects. Adequate diet, unchanging body weight within ideal values and adequate physical activities have beneficial long-term effects, first of all on preservation of bone density. Alternatives for Atrophic Changes of Vaginal Epithelium. Menopausal symptoms resulting from vaginal atrophy could be resolved by use of hydrophilic preparations, lubricants and topical lidocaine cream or 4% lidocaine water solution for dyspareunia. Conclusion. If there are contrain?dications to menopausal hormone therapy or patients are unwilling to take hormone therapy, alternative treatments, which can also solve menopausal symptoms, should be considered.

scholarly journals Menopause modulates the circulating metabolome: evidence from a prospective cohort study

2021 ◽  
Author(s):  
Jari E Karppinen ◽  
Timo Tormakangas ◽  
Urho M Kujala ◽  
Sarianna Sipila ◽  
Jari Laukkanen ◽  
...  
Keyword(s):  
Hormone Therapy ◽  
Particle Concentration ◽  
Cardiovascular Health ◽  
Ldl Cholesterol ◽  
Follicle Stimulating Hormone ◽  
Menopausal Hormone Therapy ◽  
Particle Count ◽  
Female Sex Hormones ◽  
Serum Hormone

Aims: We studied the changes in the circulating metabolome and their relation to the menopausal hormonal shift in 17β-oestradiol and follicle-stimulating hormone levels among women transitioning from perimenopause to early postmenopause. Methods and Results: We analysed longitudinal data from 218 Finnish women, 35 of whom started menopausal hormone therapy during the study. The menopausal transition was monitored with menstrual diaries and serum hormone measurements. The median follow-up was 14 months (interquartile range: 8–20). Serum metabolites were quantified with targeted nuclear magnetic resonance metabolomics. The model results were adjusted for age, follow-up duration, education, lifestyle, and multiple comparisons. Menopause was associated with 84 metabolite measures. The concentration of apoB (0.17 standard deviation [SD], 99.5% confidence interval [CI] 0.03–0.31), VLDL triglycerides (0.25 SD, CI 0.05–0.45) and particles (0.21 SD, CI 0.05–0.36), LDL cholesterol (0.17 SD, CI 0.01–0.34) and particles (0.17 SD, CI 0.03–0.31), HDL triglycerides (0.24 SD, CI 0.02–0.46), glycerol (0.32 SD, CI 0.07–0.58) and leucine increased (0.25 SD, CI 0.02–0.49). Citrate (-0.36 SD, CI -0.57 to -0.14) and 3-hydroxybutyrate concentrations decreased (-0.46 SD, CI -0.75 to -0.17). Most metabolite changes were associated with the menopausal hormonal shift. This explained 10% and 9% of the LDL cholesterol and particle concentration increase, respectively. Menopausal hormone therapy was associated with increased medium-to-large HDL particle count and decreased small-to-medium LDL particle and glycine concentration. Conclusions: Menopause is associated with proatherogenic circulating metabolome alterations. Female sex hormones levels are connected to the alterations, highlighting their impact on women's cardiovascular health.

scholarly journals Evolution of menopausal hormone therapy: from standard to ultra-low doses

2016 ◽  
pp. 74-78 ◽  
Author(s):  
V. E. Balan ◽  
A. S. Zhuravel ◽  
O. V. Lopatina ◽  
S. A. Orlova
Keyword(s):  
Hormone Therapy ◽  
Low Dose ◽  
Term Treatment ◽  
Menopausal Hormone Therapy ◽  
Vasomotor Symptoms ◽  
Hot Flushes ◽  
Low Doses ◽  
Long Term Treatment ◽  
Post Menopausal

The article tells about the incidence and severity of menopausal symptoms in women during pre-, peri- and post-menopausal periods as well as the rationale for their treatment. It was found that the use of menopausal hormone therapy (MHT) should be individualized and should not be cancelled solely due to the woman's age. The results of numerous studies of women in the transition from pre- to peri- and further to postmenopause are demonstrated. Limitations in the duration of MHT therapy are considered, and the need to develop safer therapies for long-term treatment of hot flushes is substantiated. It is proved that ultra-low-dose medication is effective for the treatment of both moderate and severe vasomotor symptoms.

Sign in / Sign up

Export Citation Format

Share Document